Author’s response to reviews

Title: Bortezomib prevents cytarabine resistance in MCL, which is characterized by downregulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Authors:
Catja Freiburghaus (catja.freiburghaus@immun.lth.se)
Venera Kuci Emruli (Venera.kuci@immun.lth.se)
Angelica Johansson (Angelica.johansson@senzagen.com)
Christian Winther Eskelund (Christianeskelund@gmail.com)
Kirsten Grønbæk (Kirsten.groenbaek@regionh.dk)
Roger Olsson (Roger.olsson@med.lu.se)
Fredrik Ek (Fredrik.ek@med.lu.se)
Mats Jerkeman (Mats.jerkeman@med.lu.se)
Sara Ek (sara.ek@immun.lth.se)

Version: 1 Date: 13 Sep 2017

Author’s response to reviews:

An Abstract section is now included in the manuscript and a clarification was added to the ethics statement.